The total number of records retrieved from this search are 38. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_1447	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	AssayXTT assay	In-vitro virus concentrationLog10 pfu/cell	In-vitro result70% cell survived 48 hours after post infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1457	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (77.79 +/- 25.08 micromolar, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell death occurs at 0.543 CI value	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1463	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (77.79 +/- 25.08 micromolar, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% cell death at CI value 0.344	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1469	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (77.79 +/- 25.08 micromolar, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell death at CI value 0.218	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1475	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (77.79 +/- 25.08 micromolar, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell death occurs at 0.004 CI value	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1481	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (77.79 +/- 25.08 micromolar, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% cell death at CI value 1 × 10⁴	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1487	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with palcitaxel (77.79 +/- 25.08 micromolar, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell death at CI value 4 × 10⁶	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1493	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (14.71+/- 6.60, ratio is 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell death at CI value 0.615	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1499	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (14.71+/- 6.60, ratio is 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% death at CI value 0.297	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1505	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (14.71+/- 6.60, ratio is 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell death at CI value 0.145	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1511	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (14.71+/- 6.60, ratio is 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell death at CI value 0.558	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1517	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (14.71+/- 6.60, ratio is 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% death at CI value 0.057	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1523	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with cisplatin (14.71+/- 6.60, ratio is 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell death at CI value 0.013	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1529	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (17.69+/- 10.16, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell death at CI value 0.112	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1535	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (17.69+/- 10.16, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75 % cell death at CI 0.030	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1541	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (17.69+/- 10.16, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell killing at CI 0.008	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1547	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (17.69+/- 10.16, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell killing at CI 0.057	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1553	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (17.69+/- 10.16, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% cell killing at CI 0.007	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1559	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Gemcitabine (17.69+/- 10.16, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell killing at CI 0.001	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1565	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(28.46+/-14.13, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell killing at CI 0.081	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1571	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(28.46+/-14.13, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% cell killing at CI 0.043	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1577	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(28.46+/-14.13, 1:20)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell killing at CI 0.023	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1583	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(28.46+/-14.13, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result50% cell killing at CI 0.027	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1589	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(28.46+/-14.13, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result75% cell killing at CI 0.006	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_1595	Virus nameReovirus	Virus strainReoT3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus combination with vinblastine(28.46+/-14.13, 1:200)	Immune gene insertion in viral genomeNo	Source of cell lineNCI	Origin of cell lineHuman NSCLC cell line	Cell lineH226	Concentration of cell lineNA	In-vitro toxicityNA	Assaychou-Talay analysis	In-vitro virus concentrationLog10 pfu/cell	In-vitro result90% cell killing at CI 0.001	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19594950
IDOV_4984	Virus nameAdenovirus	Virus strainONCOS-102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having 24 bp deletion in Rb binding site of E1A region and consisting of chmeric capsid protein and Human GM-CSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human GM-CSF gene	Source of cell lineDSMZ Germany	Origin of cell lineHuman epitheliod mesothelioma	Cell lineH226	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP per cell	In-vitro result90% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27287512
IDOV_4985	Virus nameAdenovirus	Virus strainONCOS-102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having 24 bp deletion in Rb binding site of E1A region and consisting of chmeric capsid protein and Human GM-CSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drugs pemetrexed 0.0026 mg/ml + cisplatin 0.0625	Immune gene insertion in viral genomeVirus expressing human GM-CSF gene	Source of cell lineDSMZ Germany	Origin of cell lineHuman epitheliod mesothelioma	Cell lineH226	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP per cell	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27287512
IDOV_4986	Virus nameAdenovirus	Virus strainONCOS-102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having 24 bp deletion in Rb binding site of E1A region and consisting of chmeric capsid protein and Human GM-CSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drugs pemetrexed 0.0026 mg/ml + carboplatin 0.0625	Immune gene insertion in viral genomeVirus expressing human GM-CSF gene	Source of cell lineDSMZ Germany	Origin of cell lineHuman epitheliod mesothelioma	Cell lineH226	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP per cell	In-vitro result72% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27287512
IDOV_4994	Virus nameAdenovirus	Virus strainONCOS-102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having 24 bp deletion in Rb binding site of E1A region and consisting of chmeric capsid protein and Human GM-CSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human GM-CSF gene	Source of cell lineDSMZ Germany	Origin of cell lineHuman epitheliod mesothelioma	Cell lineH226	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 VP per cell	In-vitro result100% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27287512
IDOV_4995	Virus nameAdenovirus	Virus strainONCOS-102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having 24 bp deletion in Rb binding site of E1A region and consisting of chmeric capsid protein and Human GM-CSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human GM-CSF gene	Source of cell lineDSMZ Germany	Origin of cell lineHuman epitheliod mesothelioma	Cell lineH226	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP per cell	In-vitro result90% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27287512
IDOV_4996	Virus nameAdenovirus	Virus strainONCOS-102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having 24 bp deletion in Rb binding site of E1A region and consisting of chmeric capsid protein and Human GM-CSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human GM-CSF gene	Source of cell lineDSMZ Germany	Origin of cell lineHuman epitheliod mesothelioma	Cell lineH226	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 VP per cell	In-vitro result40% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27287512
IDOV_4997	Virus nameAdenovirus	Virus strainONCOS-102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having 24 bp deletion in Rb binding site of E1A region and consisting of chmeric capsid protein and Human GM-CSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human GM-CSF gene	Source of cell lineDSMZ Germany	Origin of cell lineHuman epitheliod mesothelioma	Cell lineH226	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1000 VP per cell	In-vitro result20% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27287512
IDOV_5237	Virus nameParovirus	Virus strainwild type	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman mesothelioma cell line	Cell lineNCI-H226	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP per cell	In-vitro result10% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27783867
IDOV_5238	Virus nameParovirus	Virus strainwild type	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman mesothelioma cell line	Cell lineNCI-H226	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 VP per cell	In-vitro result2% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27783867
IDOV_5239	Virus nameParovirus	Virus strainwild type	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman mesothelioma cell line	Cell lineNCI-H226	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1000 VP per cell	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27783867
IDOV_5249	Virus nameParovirus	Virus strainAd5/3VEGFE1-delta	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationDeletion mutant for E1A gene and expressing VEGF gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman mesothelioma cell line	Cell lineNCI-H226	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP per cell	In-vitro result10% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27783867
IDOV_5250	Virus nameParovirus	Virus strainAd5/3VEGFE1-delta	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationDeletion mutant for E1A gene and expressing VEGF gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman mesothelioma cell line	Cell lineNCI-H226	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 VP per cell	In-vitro result5 % cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27783867
IDOV_5251	Virus nameParovirus	Virus strainAd5/3VEGFE1-delta	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationDeletion mutant for E1A gene and expressing VEGF gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman mesothelioma cell line	Cell lineNCI-H226	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1000 VP per cell	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27783867